Clearside Biomedical Inc CLSD:NASDAQ

Last Price$1.59NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/12/22

Today's Change+0.04(2.58%)
Bid (Size)$1.55 (22)
Ask (Size)$1.60 (4)
Day Low / High$1.56 - 1.61
Volume103.5 K

View Pharmaceuticals: Major IndustryPeer Comparison as of 08/12/2022


Clearside Biomedical Inc ( NASDAQ )

Price: $1.59
Change: +0.04 (2.58%)
Volume: 103.5 K
4:00PM ET 8/12/2022


Price: $2.87
Change: +0.16 (5.90%)
Volume: 105.7 K
4:00PM ET 8/12/2022

Aquestive Therapeutics Inc ( NASDAQ )

Price: $1.73
Change: +0.34 (24.46%)
Volume: 2.3 M
4:00PM ET 8/12/2022

aTyr Pharma Inc ( NASDAQ )

Price: $3.54
Change: -0.11 (3.01%)
Volume: 153.5 K
4:00PM ET 8/12/2022


Price: $1.68
Change: +0.09 (5.66%)
Volume: 287.2 K
4:00PM ET 8/12/2022

Read more news Recent News

--HC Wainwright Adjusts Clearside Biomedical's Price Target to $5 from $10, Keeps Buy Rating
8:10AM ET 8/10/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Clearside Biomedical Completes Dosing in Phase 1/2a Trial of CLS-AX to Treat Wet AMD Patients
9:49AM ET 7/26/2022 MT Newswires

Clearside Biomedical (CLSD) said Tuesday that dosing has been completed in cohorts 3 and 4 of its phase 1/2a clinical trial of CLS-AX in patients with...

Top Premarket Gainers
8:22AM ET 3/11/2022 MT Newswires

Excellon Resources (EXN) shares soared 89% after the company disclosed in a filing with the US Securities and Exchange Commission "high-grade" gold...

Earnings Reaction History: Clearside Biomedical Inc, 14.3% Follow-Through Indicator, 8.3% Sensitive
12:09PM ET 3/10/2022 MT Newswires

Expected Earnings Release: 03/10/2022, After-hours Avg. Extended-Hours Dollar Volume: $278,677 Clearside Biomedical Inc (CLSD) is due to issue its...

Company Profile

Business DescriptionClearside Biomedical, Inc. is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA. View company web site for more details
Address900 North Point Parkway
Alpharetta, Georgia 30005
Number of Employees50
Recent SEC Filing08/12/202210-Q
President, Chief Executive Officer & DirectorGeorge M. Lasezkay
Chief Financial OfficerCharles A. Deignan
Vice President-Engineering & ManufacturingRafael V. Andino
Vice President-Preclinical DevelopmentViral Kansara

Company Highlights

Price Open$1.57
Previous Close$1.55
52 Week Range$1.26 - 7.73
Market Capitalization$95.6 M
Shares Outstanding60.2 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement11/09/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.03
Beta vs. S&P 500N/A
Revenue$30.0 K
Net Profit Margin-5.47%
Return on Equity-6.12%

Analyst Ratings as of 06/08/2022

Consensus RecommendationConsensus Icon
Powered by Factset